A Multicenter, Open-label, Phase 2 Study to Evaluate the Efficacy and Safety of Tislelizumab in Combination With Lenvatinib in Patients With Selected Solid Tumors
Latest Information Update: 03 Jul 2024
At a glance
- Drugs Lenvatinib (Primary) ; Tislelizumab (Primary)
- Indications Colorectal cancer; Head and neck cancer; Non-small cell lung cancer; Renal cell carcinoma; Solid tumours; Squamous cell cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors BeiGene
- 04 Jun 2024 Primary results presented at the 60th Annual Meeting of the American Society of Clinical Oncology.
- 11 Jan 2024 Planned End Date changed from 1 Dec 2024 to 1 Jul 2024.
- 13 Oct 2023 Status changed from recruiting to active, no longer recruiting.